Efficacy Of Combined Use Of Budesonide Inhalation In The Treatment Of Chronic Obstructive Pulmonary Disease

Recent studies show that, due to various factors of air pollution, smoking, the aging of the population, the incidence of chronic obstructive pulmonary disease(COPD) in china increased year by year, has become a common respiratory disease, which cause serious damage to the body health, more and more get the wide attention of the society. In recent years, in the treatment drugs of COPD, glucocorticoid can fight inflammatory mediators, suppress airway inflammation from several aspects, has a good effect to increase exercise tolerance in patients with acute exacerbation of reducing seizure frequency and improve the quality of life of patients, etc.It has been included in a new chronic obstructive pulmonary disease global Initiative(GOLD) program, widely used in chronic obstructive pulmonary disease with acute exacerbation(AECOPD) anti-inflammatory treatment. ObjectiveBy observing AECOPD patients treated with conventional therapy and conventional therapy combined with budesonide nebulized inhalation changes in pulmonary function before and after treatment,Evaluate differences in the two kinds of treatment methods for improving the efficacy of pulmonary function in patients with AECOPD, explore the effect of budesonide for the treatment of patients with AECOPD disease, relieve the clinical symptoms of patients with AECOPD, clinicians use budesonide treatment AECOPD patients accumulate more treatment experience. MethodsAccording to the diagnostic criteria in《 Chronic obstructive pulmonary disease diagnosis and treatment standard》(2007 revised edition) released by the Chinese Medical Association Respiratory Diseases Chronic Obstructive Pulmonary Disease Study Group, Collect patient records with AECOPD in the department of respiration in Affiliated Hospital of Taishan Medical University in2011-2013, 40 patients were randomly divided into conventional group and treatment group, the conventional group 20 cases, the treatment group of 20 cases, Packet to ensure that no significant differences between the 2 groups in gender, age, smoking history, disease duration, disease severity and so on, with statistically comparable.Pulmonary function tests were performed before the two groups of patients before treatment.The conventional group was given to maintain airway patency, continuous low flow oxygen,bronchodilators, control of infection, cough and phlegm, maintain water, electrolyte, acid-base balance, nutritional support and other comprehensive therapy.On this basis, the treatment group combined with budesonide(trade name: Pulmicort, Astra Zeneca Australia Ltd) 2ml(1mg) inhalation, 2 times a day, Methods used in strict accordance with the instruction on the steps. give the pulmonary function tests At the time of discharge again. Based on the statistical analysis of the indicators of pulmonary function tests measured before and after the treatment in patients, understand the different clinical efficacy between the combination of nebulized budesonide after treatment with conventional therapy in AECOPD patientsPulmonary function parameters including the forced expiratory volume in one second(FEV1), forced expiratory volume in the first second percentage of forced vital capacity(FEV1/FVC%) and FEV1 percent predicted(FEV1%pred) and other key indicators. ResultAfter treatment, the indicators showed significant improvement in pulmonary function in patients with varying degrees of( P<0.01). And pulmonary function in the treatment group after treatment is better than that of conventional group( P<0.05). The treatment group was observed no adverse reactions during treatment. Conclusion and significanceChronic obstructive pulmonary disease(COPD) is a common respiratory disease, Its main feature is persistent airflow limitation and limited airflow is irreversible,and progressive,Pulmonary function tests to determine the airflow limitation is a very important reference value. After inhaled bronchodilators, if one second forced expiratory volume occupied by the percentage of forced vital capacity(FEV1/FVC%) <70%, indicating the presence of persistent airflow limitation. This results showed that, after treatment, the two groups of patients on pulmonary function index had different degrees of improvement(P<0.01), But with budesonide treatment group had better effect than the conventional group(P<0.05), and the treatment group had no obvious blood sugar, high blood pressure and other adverse reactions. It is considered the treatment of patients with chronic obstructive pulmonary disease with acute exacerbation(AECOPD), On the basis of giving active comprehensive conventional therapy,early application of budesonide inhalation treatment, has the advantages of asmall dose,site of action limitations,mild systemic adverse reactions,and so on,Can achieve satisfactory curative effect while reducing the adverse reaction of excessive or systemic using of glucocorticoids,is helpful for clinical rational use of glucocorticoid drugs, accumulate more experience, for experience of developing treatment plan, reasonable social and economic benefits ratio, is worthy of clinical promotion.